The three pharmaceutical companies listed on the Bucharest StockExchange, Antibiotice Iasi (ATB), Zentiva Bucuresti (SCD) andBiofarm Bucuresti (BIO), for this year project turnover growth ofabove 10%, after they saw slightly sliding turnovers last year,according to the budget drafts to be submitted to shareholderapproval. Antibiotice Iasi, the biggest drug maker on the StockExchange in terms of turnover, forecasts revenues worth 248m RON(60m euros against a 4.1 RON/EUR exchange rate), up 12% from lastyear, when the company's revenues dropped by 4%. The company,controlled by the state through the Health Ministry, also expects23% higher income, to 14.7m RON (3.58m euros). Czech Zentiva boaststhe most upbeat scenario for this year, targeting 22% higherturnover, to 215m RON (52m euros), as well as operating income of40m RON (almost 10m euros). Last year, it posted with operatinglosses of 10.3m RON and ended the year with 2.88m RON (0.7m euros)losses. Biofarm Bucuresti sees its turnover rise by 11.1%, to 74.5mRON (18.1m euros), but net income shrink by 31%, to 13.4m RON (3.2meuros).
Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels
